TICKERNERD
Menu
NVNONVNOHealthcare · Medical Devices

NVNO Stock Forecast: enVVeno Medical Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$11
+7.80% on the day

The 1 Wall Street analysts covering enVVeno Medical Corp. hold a median 12-month price target of $30 — +167.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.6M
Ticker Nerd rank
33 / 100
Median analyst target
$30
Analysts covering
1
Total return, dividends reinvested
1W
+1.9%
1M
+10.3%
YTD
−0.3%
1Y
−67.0%
From 52W high
−68.0%
From 52W low
+29.2%
$9
$35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NVNO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores enVVeno Medical Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Growth
86
Accruals
67
Issuance
49
Revisions
45
Quality
24
Volatility
22
Value
4
Momentum
1

Size (95): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NVNO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NVNO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26NVNOHigh $30Median $30Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $30Median $30High $30

The green dot is the last close — the median target sits +167.9% from it.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NVNO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NVNO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

enVVeno Medical Corp. (NVNO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 79% of US stocks

Price / sales
—
Price / book
0.3×

Cheaper than 88% of US stocks

EV / EBITDA
0.8×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−58.5%

Higher than 19% of US stocks

Return on assets
−36.7%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NVNO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NVNOenVVeno Medical Corp.$7.6M
33
AIDX20/20 Biolabs, Inc.$6.8M
5
ICCMIceCure Medical Ltd.$6.8M
38
NXLNexalin Technology, Inc.$7.3M
38
PMIPicard Medical, Inc.$7.5M
33
CODXCo-Diagnostics, Inc.$7.6M
37
INBSIntelligent Bio Solutions, Inc.$7.6M
9

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own enVVeno Medical Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NVNO news & analysis

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments

Accesswire · 4 Aug 2026positive

enVVeno Medical announced the publication of a peer-reviewed health economic analysis in the Journal of Vascular Surgery: Venous and Lymphatic Disorders. The study found that its replacement venous valve therapy is economically dominant versus standard-of-care treatments for deep venous CVI, projecting over $32,000 in healthcare savings per patient over five years and fewer venous ulcers per patient. The company said the evidence will support future coverage determinations and reimbursement policies for its enVVe device.

Why it matters — NVNO watchers would care because the peer-reviewed economic data supporting reimbursement and coverage could strengthen the business case for enVVe adoption.

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

Accesswire · 31 July 2026positive

enVVeno Medical reported second quarter 2026 financial results and highlighted receiving FDA IDE approval to begin the TAVVE pivotal trial for its enVVe System, a non-surgical replacement venous valve for severe deep chronic venous insufficiency. Patient enrollment for the pivotal study is expected to start in the second half of 2026, with cash runway extending into the third quarter of 2027.

Why it matters — This marks the first-ever FDA IDE approval for a U.S. pivotal study of a transcatheter replacement venous valve, bringing enVVeno's enVVe System closer to potential commercialization for patients with severe deep CVI.

FAQ

Frequently asked questions about NVNO stock

What is the NVNO stock price forecast for 2026-2027?

The 1 Wall Street analysts covering enVVeno Medical Corp. have a median 12-month price target of $30, with estimates ranging from $30 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NVNO stock a buy right now?

Of the 1 analysts covering enVVeno Medical Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks enVVeno Medical Corp. 33 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NVNO?

As at 22 Aug 2026, enVVeno Medical Corp. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

Will NVNO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +167.9% from the last close, and Ticker Nerd's factor model ranks enVVeno Medical Corp. 33 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NVNO stock forecast for 2030?

No analyst covering enVVeno Medical Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVNO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $30 over the next 12 months.

How has NVNO stock performed over the past year?

enVVeno Medical Corp. returned -67.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does enVVeno Medical Corp. do?

EnVVeno Medical Corporation is a biomedical company focused on the development and commercialization of innovative medical treatments. Primarily, the corporation is dedicated to addressing unmet medical needs pertaining to vascular diseases, with a notable emphasis on venous conditions.

What is the latest news on NVNO?

The most recent item we track (Accesswire, 4 Aug 2026): "Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments". enVVeno Medical announced the publication of a peer-reviewed health economic analysis in the Journal of Vascular Surgery: Venous and Lymphatic Disorders. The study found that its replacement venous valve therapy is economically dominant versus standard-of-care treatments for deep venous CVI, projecting over $32,000 in healthcare savings per patient over five years and fewer venous ulcers per patient. The company said the evidence will support future coverage determinations and reimbursement policies for its enVVe device.

Company

About enVVeno Medical Corp.

EnVVeno Medical Corporation is a biomedical company focused on the development and commercialization of innovative medical treatments. Primarily, the corporation is dedicated to addressing unmet medical needs pertaining to vascular diseases, with a notable emphasis on venous conditions. The company's flagship product centers around a specialized prosthetic device aimed at treating chronic venous insufficiency (CVI), a condition prevalent due to valve failure in veins, leading to poor circulation and various complications. EnVVeno Medical's research and development efforts are channeled towards creating effective solutions that improve patient outcomes and enhance quality of life for individuals affected by these vascular issues. Operating within the healthcare and biotechnology sector, EnVVeno Medical is a key contributor to advancements in medical technology, with its innovative approach underscoring its importance in the medical devices market. By prioritizing cardiovascular health, the corporation plays a critical role in the healthcare industry, supporting the broader objective of developing cutting-edge treatments and addressing critical health challenges.

CEO Mr. Robert A. Berman · 37 employees · United States · https://www.envveno.com